Development of a Weighted-Incidence Syndromic Combination Antibiogram (WISCA) to guide the choice of the empiric antibiotic treatment for urinary tract infection in paediatric patients: a Bayesian approach

Abstract Background To evaluate the ability of Weighted-Incidence Syndromic Combination Antibiograms (WISCA) to inform the selection of empirical antibiotic regimens for suspected paediatric community-acquired urinary tract infections. Methods Data were collected from outpatients (< 15 years) acc...

Full description

Bibliographic Details
Main Authors: Elisa Barbieri, Daniele Bottigliengo, Matteo Tellini, Chiara Minotti, Mara Marchiori, Paola Cavicchioli, Dario Gregori, Carlo Giaquinto, Liviana Da Dalt, Daniele Donà
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Antimicrobial Resistance and Infection Control
Subjects:
Online Access:https://doi.org/10.1186/s13756-021-00939-2
Description
Summary:Abstract Background To evaluate the ability of Weighted-Incidence Syndromic Combination Antibiograms (WISCA) to inform the selection of empirical antibiotic regimens for suspected paediatric community-acquired urinary tract infections. Methods Data were collected from outpatients (< 15 years) accessing the emergency rooms of Padua University-Hospital and Mestre Dell' Angelo-Hospital (Venice) between January 1st, 2016, and December 31st, 2018. WISCAs were developed by estimating the coverage of eight regimens using a Bayesian hierarchical model adjusted for age, sex, and previous antibiotic treatment or renal/urological comorbidities. Results 385 of 620 urine culture requests were included in the model analysis. The most frequently observed bacterium was E. coli (85% and 87%, Centre A and B). No centre effect on coverage estimates was found, and data were successfully pooled together. Coverage ranged from 77.8% (Co-trimoxazole) to 97.6% (Carbapenems). Complex cases and males had significantly lower odds of being covered by a regimen than non-complex cases and females (odds ratio (OR) 0.49 [95% HDI, 0.38–0.65], and OR: 0.73 [95% HDIs, 0.56–0.96] respectively). Children aged 3–5 years had lower odds of being covered by a regimen than other age groups, except for neonates. Conclusions The developed WISCAs provide highly informative estimates on coverage patterns overcoming the limitation of combination antibiograms and expanding the framework of previous Bayesian WISCA algorithm.
ISSN:2047-2994